GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (LTS:0RGO) » Definitions » Return-on-Tangible-Equity

DMS Imaging (LTS:0RGO) Return-on-Tangible-Equity : -89.18% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. DMS Imaging's annualized net income for the quarter that ended in Dec. 2023 was €-2.87 Mil. DMS Imaging's average shareholder tangible equity for the quarter that ended in Dec. 2023 was €3.22 Mil. Therefore, DMS Imaging's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -89.18%.

The historical rank and industry rank for DMS Imaging's Return-on-Tangible-Equity or its related term are showing as below:

LTS:0RGO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1366.74   Med: -184.17   Max: -20.55
Current: -20.55

During the past 12 years, DMS Imaging's highest Return-on-Tangible-Equity was -20.55%. The lowest was -1,366.74%. And the median was -184.17%.

LTS:0RGO's Return-on-Tangible-Equity is ranked better than
67% of 1306 companies
in the Biotechnology industry
Industry Median: -46.86 vs LTS:0RGO: -20.55

DMS Imaging Return-on-Tangible-Equity Historical Data

The historical data trend for DMS Imaging's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging Return-on-Tangible-Equity Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,366.74 - - -130.64 -22.93

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -153.44 -64.35 35.88 -89.18

Competitive Comparison of DMS Imaging's Return-on-Tangible-Equity

For the Biotechnology subindustry, DMS Imaging's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where DMS Imaging's Return-on-Tangible-Equity falls into.



DMS Imaging Return-on-Tangible-Equity Calculation

DMS Imaging's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.709/( (3.917+2.266 )/ 2 )
=-0.709/3.0915
=-22.93 %

DMS Imaging's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-2.868/( (4.166+2.266)/ 2 )
=-2.868/3.216
=-89.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


DMS Imaging  (LTS:0RGO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


DMS Imaging Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of DMS Imaging's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (LTS:0RGO) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (LTS:0RGO) Headlines

No Headlines